SMAD2 and pulmonary fibrosis: Mangiferin reduced BLM‐induced inflammation and pulmonary fibrosis by inhibiting the TLR4/p65 pathway and the EMT process through interruption of the TGF‐β1/Smad2/3 pathway in mice [32].